Boston Scientific Expands EP Technologies

Two agreements will provide new technologies for the electrophysiology business of Boston Scientific (Natick, MA, USA).

The company has made an equity investment in Super Dimension, Ltd. (Herzliya, Israel) and obtained a license to incorporate its localization sensors and navigational technology into diagnostic mapping, intracardiac ultrasound, and therapeutic electrophysiology catheters manufactured by Boston's Electrophysiology (EP) Technologies division. Catheter navigation localization technology allows doctors to more accurately ablate electrical problems in the heart while reducing procedure time. The nonfluoroscopic guidance technology should also help reduce radiation exposure to the patient and doctor.

In a separate agreement with Cath Data, Inc. (Toronto, Canada), Boston Scientific has purchased Cath Data's QMS 2 advanced mapping technology. This acquisition positions both companies for more rapid success in the joint development of software enhancements and technology platform improvements to the QMS 2 system, according to Boston Scientific. Accurate mapping of the heart's electrical signals enables doctors to guide an ablation catheter to a target site to destroy malfunctioning tissue.

"The Super Dimension and Cath Data technologies are clearly synergistic, and they combine to strengthen Boston Scientific's position as a leader in cardiac electrophysiology,” said Tom Coen, president of EP Technologies.”



Related Links:
Boston Scientific